Company Filing History:
1 out of 832,843 Years Active: 2023
Title: Robin Lytle: Innovator in Monoclonal Antibody Research
Introduction
Robin Lytle is an accomplished inventor based in Acton, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on creating innovative solutions for medical diagnostics and treatments.
Latest Patents
Robin Lytle holds a patent for a monoclonal antibody directed to FGFR1. This invention relates to antibodies that specifically bind to and neutralize human, macaque, and mouse forms of FGFR1 with high affinity. The patent also encompasses nucleic acids encoding these antibodies, vectors for their expression, and host cells for their production. Furthermore, the invention highlights the use of these antibodies in the diagnosis and treatment of various cancers.
Career Highlights
Throughout his career, Robin has demonstrated a commitment to advancing medical science through his innovative research. His patent reflects his expertise in antibody development and its potential applications in cancer therapy.
Collaborations
Robin has collaborated with notable colleagues in his field, including Christel Iffland and Christina Esdar. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Robin Lytle's work in monoclonal antibody research exemplifies the impact of innovation in the medical field. His contributions are paving the way for new diagnostic and therapeutic options for cancer treatment.